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ABSTRACT
Background: We sought to estimate the national prevalence of HPV vaccine refusal and delay in a
nationally-representative sample of parents of adolescents. We also compared parents who refused versus
delayed HPV vaccine in terms of their vaccination beliefs and clinical communication preferences.
Methods: In 2014 to 2015, we conducted an online survey of 1,484 US parents who reported on an 11- to
17-year-old child in their household. We used weighted multinomial logistic regression to assess correlates
of HPV vaccine refusal and delay. Results: Overall, 28% of parents reported that they had ever “refused or
decided not to get” HPV vaccine for their child, and an additional 8% of parents reported that they had
“delayed or put off getting” HPV vaccine. Compared to no refusal/delay, refusal was associated with lower
confidence in adolescent vaccination (relative risk ratio [RRR] D 0.66, 95% confidence interval [CI], 0.48–
0.91), lower perceived HPV vaccine effectiveness (RRR D 0.68, 95% CI, 0.50–0.91), and higher perceived
harms (RRR D 3.49, 95% CI, 2.65–4.60). In contrast, delay was associated with needing more information
(RRR D 1.76, 95% CI, 1.08–2.85). Most parents rated physicians and information sheets as helpful for
making decisions about HPV vaccination, although parents who reported refusal endorsed these
resources less often. Conclusions: Our findings suggest that HPV vaccine refusal is common among
parents of adolescents and may have increased relative to previous estimates. Because the vaccination
beliefs and communication preferences of parents who refuse appear to differ from those who delay,
targeted communication strategies may be needed to effectively address HPV vaccine hesitancy.
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Human papillomavirus (HPV) vaccination coverage among US
adolescents remains far below national goals with just 42% of girls
and 28% of boys completing the 3-dose series by 2015.1 In the
extensive research literature that seeks to explain lowHPV vaccina-
tion coverage, many studies have focused on parents of adolescents
because they are most often responsible for making HPV vaccina-
tion decisions.2 These studies, including our own, have typically
examined the relationship between parents’ vaccination beliefs,
their intention to vaccinate their adolescents, and adolescents’ ulti-
mate vaccination status.3-6 This research has been important for
identifying potentially modifiable barriers to HPV vaccination,
such as parents’ need for more information and their perception
that their children’s risk of HPV infection is low.3-6 However,
despite the large volume of existing literature, basic gaps in our
understanding of parents’ decisionmaking processes remain.
Most notably, we know surprisingly little about the epidemi-
ology of HPV vaccine refusal and delay. These behaviors consti-
tute important intermediary steps between parents’ vaccination
intentions and adolescents’ vaccination status. Although the
qualitative literature suggests that HPV vaccine refusal and delay
are common,7,8 only one study has estimated their national prev-
alence.9 In 2010, a special addendum to the National Immuniza-
tion Survey (NIS)-Teen assessed these behaviors, finding that
20% of parents of adolescent girls reported HPV vaccine refusal
while an additional 11% reported delay.9 Understanding parental
refusal and delay of HPV vaccine is important for preventing
these behaviors, but unfortunately, little is known about how the
prevalence of HPV vaccine refusal and delay has changed since
2010, whether prevalence is different for boys vs. girls, or how
parents who refuse differ from those who delay.
We sought to better understand HPV vaccine refusal and
delay using data from a nationally-representative sample of
parents of adolescents. The aims of this study were to: 1)
estimate the national prevalence of HPV vaccine refusal and
delay; 2) assess demographic and psychological correlates of
refusal and delay; 3) compare parents’ reasons for refusal
versus delay; and 4) assess differences in parents’ communi-
cation preference according to their refusal/delay status.
Results
Sample characteristics
About half (51%) of index children were male, and the mean
age of children in the sample was 14 y (Table 1). Most were
non-Hispanic white (58%), non-Hispanic black (12%), or
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Hispanic (21%). On indicators of socioeconomic status, over
one-third of parents (39%) reported having a high school
degree or less education and about one-fifth (22%) reported a
household income of less than $35,000 per year.
HPV vaccine refusal and delay, vaccination status, and
intention to vaccinate
Full sample. Overall, 28% of parents reported having ever
refused HPV vaccine, 8% reported delay, and 64% reported nei-
ther refusal nor delay. HPV vaccine initiation was less common
among adolescents whose parents had ever refused (27%) vs.
delayed (59%) or neither (56%) (p < 0.05) (Fig. 1). Among
unvaccinated adolescents (n D 799), intention to get HPV vac-
cine was also lower among parents who reported refusal (46/
321 or 14%) versus delay (30/48 or 66%) or neither (152/430 or
37%) (p < 0.05).
Girls, ages 13–17. For 13- to 17-year-old girls (n D 535), 169
parents (30%) reported having ever refused HPV vaccine, 61
parents (12%) reported delay, and 305 parents (58%) reported
neither refusal nor delay. The proportion of girls who had initi-
ated the HPV vaccine series was about one-third for those
whose parents reported refusal (54/169 or 31%) vs. about
two-thirds for those whose parents reported delay (42/61 or
64%) or neither (219/305 or 73%). Among unvaccinated girls
(n D 220), intention to get HPV vaccine was lower among
parents who reported refusal (15/115 or 13%) versus delay
(15/19 or 81%) or neither (34/86 or 41%).
Correlates of HPV vaccine refusal and delay
Refusal. Compared to no refusal/delay, HPV vaccine refusal
was more common among parents from households with high
vs. low income (relative risk ratio [RRR] D 1.48, 95% confi-
dence interval [CI], 1.02–2.15, Table 2). Refusal was less com-
mon among parents who had high confidence in adolescent
vaccination (RRR D 0.66, 95% CI, 0.48–0.91) or perceived high
HPV vaccine effectiveness (RRR D 0.68, 95% CI, 0.50–0.91).
Refusal was more common among parents who perceived high
potential harm from HPV vaccination (RRR D 3.49, 95% CI,
2.65–4.60). Refusal was not associated with children’s sex, age,
or race/ethnicity, or with parents’ educational attainment or
uncertainty about HPV vaccine.
Delay. Compared to no refusal/delay, HPV vaccine delay
was more common among parents reporting on female versus
male children (RRR D 1.74, 95% CI, 1.14–2.65) and older
children, ages 16–17, vs. younger children, ages 11–12 (RRR D
2.04, 95% CI, 1.16–3.59). Delay was also more common among
parents who reported high uncertainty about HPV vaccine
(RRR D 1.76, 95% CI, 1.08–2.85). Delay was not associated
with children’s race/ethnicity, parents’ educational attainment,
annual household income, or parents’ perceptions of HPV vac-
cine effectiveness, harms, or vaccination confidence.
Reasons for HPV vaccine refusal and delay
Parents who refused versus delayed HPV vaccine more often
reported their reason was believing their child was not sexually
active (57% vs. 41%, Fig. 2), concern about lasting health prob-
lems (50% versus 24%), or believing their child did not need
HPV vaccine (34% vs. 10%, all p < 0.01). Similar proportions
of parents who refused versus delayed indicated needing more
information as their reason (44% vs. 53%). Parents who refused
or delayed less often reported their reason was concern about
HPV vaccine effectiveness (19% versus 5%) or concern about
short-term health problems (18% vs. 9%).
Clinical communication preferences
Helpful sources of information. Overall, a majority of parents
(75%) said talking to a doctor would be helpful when deciding
about HPV vaccination, although parents reporting HPV
Table 1. Sample characteristics (n D 1,484).
n (%)
Child characteristics
Sex
Male 751 (51)
Female 733 (49)
Age (years)
11–12 415 (29)
13–15 626 (42)
16–17 443 (29)
Race
Non-Hispanic white 972 (58)
Non-Hispanic black 146 (12)
Hispanic 256 (21)
Other 110 (9)
HPV vaccination status
0 doses 799 (52)
1 dose 685 (48)
Parent characteristics
Sex
Male 659 (44)
Female 825 (56)
Educational attainment
High school degree or less 570 (39)
Some college, no degree 383 (32)
College degree or more 531 (29)
Household characteristics
Annual income
<$35,000 323 (22)
$35,000-$74,999 465 (30)
$75,000 696 (48)
Region
Northeast 256 (18)
Midwest 389 (22)
South 493 (37)
West 346 (24)
Note: Table shows raw frequencies and weighted percentages.
Figure 1. HPV vaccination status and intention to vaccinate for adolescents whose
parents reported having ever refused HPV vaccine (n D 432), delayed HPV vaccine
(n D 118), or neither (n D 934).
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vaccine refusal (61%) endorsed this response less often than
those reporting delay (79%) or neither refusal nor delay (81%)
(Table 3, Fig. 3). About half of parents (53%) perceived reading
an information sheet as being helpful, with parents who
reported delay (71%) more often endorsing this option than
those reporting refusal (54%) or neither (50%). Parents less
often perceived talking to a nurse (19%) or watching an infor-
mational video (21%) as being helpful.
Table 2. Multivariable correlates of HPV vaccine refusal and delay (n D 1,484)
Parents reporting HPV
vaccine refusal/ Total
parents in categorya (%)
Multivariable
RRR (95% CI)
Parents reporting HPV
vaccine delay/ Total
parents in categoryb (%)
Multivariable
RRR (95% CI)
Child characteristics
Sex
Male 204/703 (29) 1 48/547 (8) 1
Female 228/663 (33) 1.29 (0.99-1.68) 70/505 (14) 1.74 (1.14-2.65)
Age (years)
11-12 117/391 (29) 1 24/298 (7) 1
13-15 187/574 (31) 1.15 (0.83-1.59) 52/439 (11) 1.57 (0.91-2.72)
16-17 128/401 (32) 1.23 (0.87-1.75) 42/315 (14) 2.04 (1.16-3.59)
Race
Non-Hispanic white 303/896 (34) 1 76/669 (11) 1
Non-Hispanic black 32/130 (27) 0.78 (0.49-1.25) 16/114 (15) 1.42 (0.74-2.72)
Hispanic 71/236 (29) 0.93 (0.65-1.33) 20/185 (10) 0.84 (0.47-1.50)
Other 26/104 (22) 0.59 (0.34-1.00) 6/84 (7) 0.57 (0.23-1.39)
Parent characteristics
Educational attainment
High school degree or less 151/516 (28) – 54/419 (12) –
Some college 117/359 (33) – 24/266 (9) –
College degree or more 164/491 (33) – 40/367 (11) –
Household characteristics
Annual income
Less than $35,000 78/296 (26) 1 27/245 (11) 1
$35,000-$74,999 139/428 (31) 1.28 (0.86-1.89) 37/326 (11) 0.97 (0.53-1.79)
$75,000 or more 215/642 (33) 1.48 (1.02-2.15) 54/481 (11) 1.03 (0.58-1.84)
Perceptions
Effectiveness of HPV vaccine
Low 304/818 (36) 1 65/579 (11) 1
High 128/548 (23) 0.68 (0.50-0.91) 53/473 (11) 1.18 (0.77-1.83)
Harms of HPV vaccine
Low 191/878 (21) 1 90/777 (11) 1
High 241/488 (50) 3.49 (2.65-4.60) 28/275 (10) 0.76 (0.45-1.28)
Uncertainty about HPV
vaccine
Low 278/937 (28) 1 74/733 (10) 1
High 154/429 (37) 1.05 (0.78-1.42) 44/319 (14) 1.76 (1.08-2.85)
Vaccination confidence
Low 123/278 (42) 1 18/173 (10) 1
High 309/1,088 (28) 0.66 (0.48-0.91) 100/879 (11) 1.07 (0.59-1.94)
Note. Table shows raw frequencies and weighted percentages and relative risk ratios. Analyses used multinomial logistic regression, with neither refusal nor delay (n D
934) compared simultaneously to refusal (n D 432) and delay (n D 118). HPV: human papillomavirus. RRR: relative risk ratio. CI: confidence interval. Dashes (–) indicate
the variable was not included in the multivariable model because it was not statistically significant at the bivariate level.
aDenominator consists of parents who reported: 1) refusal; and 2) neither refusal nor delay.
bDenominator consists of parents who reported: 1) delay; and 2) neither refusal nor delay.
p < 0.05
p < 0.01
Figure 2. Reasons parents refused (n D 432) or delayed (n D 118) HPV vaccine.
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Preferred age for provider recommendation. Overall, few
parents (16%) believed providers should never routinely rec-
ommend HPV vaccine, although this perception was more
common among parents reporting refusal (30%) versus delay
(4%) or neither (12%). Most parents believed that providers
should begin recommending HPV vaccine to adolescents on
time by age 12 (39%) or behind schedule at age 13 or later
(45%). Parents reporting delay (60%) more often indicated a
preference for behind schedule recommendations compared
to those reporting refusal (44%) or neither (44%).
Decisional timeframe. Overall, most parents preferred to
make a same-day decision about HPV vaccination with little or
no discussion (42%) or to make the decision at a later visit
(42%). Parents who reported refusal (60%) or delay (51%)
more often indicated a preference for deciding at a later visit
compared to those reporting neither (33%). Few parents (16%)
preferred a long discussion with their child’s provider.
Discussion
We found that HPV vaccine refusal and delay were prevalent in
our nationally-representative sample of parents of adolescents.
Overall, 28% of parents reported having ever refused HPV vac-
cine, and consistent with prior research,9,17 this behavior was
more common among parents from high- vs. low-income
households. In terms of change over time, our estimate for the
prevalence of HPV vaccine refusal for 13- to 17-year-old girls
was substantially higher than what the NIS-Teen reported,
using the same measures, for 2010 (30% versus 20%, respec-
tively).9 This finding suggests that refusal may have become
more common in recent years, which could be, in part, because
providers are recommending HPV vaccination more often,
thereby giving parents more opportunities to refuse.5,18 Alter-
natively, the change in refusal prevalence could reflect an
increase in parents’ concerns or a mode effect, whereby parents
were more comfortable reporting refusal in our online survey
vs. during the telephone interviews conducted for NIS-Teen.18
Whatever the case, this finding is troubling given that vaccine
refusal is associated with under-immunization and constitutes
a considerable burden to the healthcare system in terms of pro-
vider time and frustration.9,19 Ongoing surveillance is needed
to provide a better understanding of HPV vaccine refusal over
time.
In addition to refusal, 8% of parents reported HPV vaccine
delay. In terms of demographic variation, delay was more com-
mon among parents of girls versus boys and older vs. younger
adolescents. For 13- to 17-year-old girls, our estimate of the
proportion of parents who delayed HPV vaccine was very simi-
lar to that reported by NIS-Teen in 2010 (12% versus 11%).9
This finding suggests that the prevalence of delay has remained
stable over time.
Parents who refused vs. delayed HPV vaccine differed in
terms of their vaccination behavior and intentions. Among
parents with a history of refusal, over one-third (37%) went on
to initiate HPV vaccination or intended to do so in the next
year. Among parents with a history of delay, well over three-
quarters (86%) initiated HPV vaccination or intended to do so.
In this way, parents who delayed were similar to those who had
neither refused nor delayed. Taken together, these findings sug-
gest that providers should not give up when they encounter
HPV vaccine hesitancy because many parents eventually
change their minds and accept HPV vaccine. By continuing to
offer counseling and recommendations, providers may have
considerable success in raising HPV vaccination coverage
among their adolescent patient populations.
In addition to vaccination behavior, concerns appeared to
differ for parents who refused versus delayed HPV vaccine.
Correlates of vaccine refusal included lower overall confidence
in adolescent vaccination generally as well as lower perceived
effectiveness and higher perceived harms of HPV vaccination
Table 3. Parents’ preferences for clinical communication about HPV vaccination (n D 1,484).
Parents reporting HPV vaccine
refusal (n D 432) n (%)
Parents reporting HPV vaccine
delay (n D 118) n (%)
Parents reporting neither refusal
nor delay (n D 934) n (%)
Helpful sources of information
Talking to a doctor 257 (61) 92 (79) 762 (81)
Talking to a nurse 78 (18) 29 (23) 179 (19)
Reading an info sheet 235 (54) 84 (71) 479 (50)
Watching a video 94 (22) 27 (22) 197 (20)
Age for provider recommendation
On time (12 years of age) 97 (26) 44 (37) 422 (45)
Late (13 years of age) 196 (44) 69 (60) 401 (44)
Never 139 (30) 5 (4) 111 (12)
Decisional timeframe
Same-day, minimal discussion 131 (31) 37 (31) 452 (48)
Same-day, long discussion 41 (10) 19 (19) 173 (19)
Later visit 260 (60) 62 (51) 309 (33)
Note. Table shows raw frequencies and weighted percentages. HPV: human papillomavirus.
Figure 3. Perceived helpfulness of clinical information sources about HPV
vaccination.
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specifically. When asked their reasons for refusal, parents most
often reported believing their child was not sexually active and
concern about lasting health problems. By contrast, the only
psychological correlate of vaccine delay was higher uncertainty,
with parents’ most common reason for delay being the need for
more information. These findings suggest that HPV vaccine
refusal may be motivated by specific and sometimes serious
concerns that correspond to the Health Belief Model’s con-
structs of perceived benefits and threats,6,20 with delay stem-
ming from a more generalized feeling of ambivalence. If so,
persuading the “fence sitters” who delay may be a fairly
straightforward matter of providing information, while the
“worried” who refuse may require more extensive and targeted
counseling [21, p. 84–85].
In terms of how to provide such counseling, parents
reported differences in their clinical communication
preferences according to their history of HPV vaccine refusal
or delay. Consistent with prior research,22,23 most respondents
indicated that talking to a physician or reading an information
sheet would be helpful for making a decision about HPV
vaccination, although parents who reported refusal less often
perceived these resources to be helpful. We were encouraged
to note that, across respondent groups, relatively few parents
believed that providers should never routinely recommend
HPV vaccine. Similarly, few parents in any group perceived
the need for long discussions about HPV vaccination. We did
find, however, that over half of parents who reported delay
indicated a preference for receiving recommendations behind
schedule, and many parents in both groups preferred to make
a decision about HPV vaccination at a visit subsequent to
receiving a recommendation. These preferences likely pose a
barrier to the timely delivery of HPV vaccine and suggest the
need for providers to emphasize the advantages of “on time”
HPV vaccination, which include convenience and enhanced
protection against HPV.5
The findings of our study point to several areas for future
research. First, given the differences we observed among
parents who refused vs. delayed HPV vaccine, researchers
should seek to evaluate targeted strategies for providing
information to vaccine hesitant parents. By identifying and
addressing parents’ specific concerns, providers may be able
to counsel parents more effectively and efficiently, which is an
important goal given providers’ perception that discussing
HPV vaccine takes far longer than other adolescent vaccines.24
Second, because many parents in our sample indicated a
preference for deciding about HPV vaccination after receiving
a recommendation, future research should explore the impact
of providing anticipatory guidance about adolescent vaccina-
tion. By giving parents prior notice that their children will be
due to receive HPV vaccine, providers may be able to give
parents more time to prepare.9,25 Finally, given the dearth of
data on HPV vaccine refusal and delay, additional research is
needed to explore topics such as why parents who initially
refuse or delay HPV vaccine later go on to get the vaccine.
Understanding how parental refusal and delay interact with
other key determinants of under-immunization (e.g., absent
or low-quality provider recommendations) is also important.
Strengths of this study include a large, nationally-representa-
tive sample and a good response rate. To our knowledge, this
study is the first to assess the national prevalence of HPV refusal
and delay since the 2010 NIS-Teen. Surveillance of these behav-
iors is important given that refusal and delay are specific to
parents’ role in vaccine delivery, unlike vaccination status which
reflects a combination of parent-, provider-, and health systems-
related factors. Limitations of this study include its cross-
sectional design which prevents us from assessing the temporal
relationship between HPV vaccine refusal and delay and parents’
vaccination behavior and concerns. That our measures rely on
parents’ self-report is also a limitation. Future research can build
on the present study by prospectively assessing the relationship
between parents’ concerns and their decisions to refuse, delay, or
accept HPV vaccine and by validating parental report of refusal
and delay with provider-reported measures.
Conclusion
Parents who refused HPV vaccine differed from those who
delayed in terms of their vaccination behavior, concerns, and
communication preferences. While parents who delayed were
distinguished only by their need for more information, parents
who refused had distinct concerns and less often initiated or
intended to initiate HPV vaccination. Relatively few parents in
our sample were opposed to provider recommendations for
HPV vaccination, but many who delayed expressed a prefer-
ence for receiving recommendations behind schedule. Further-
more, only about half of parents who refused or delayed
preferred same-day vaccination. Since many parents who
refused or delayed went on to get HPV vaccine, our findings
suggest that providers who encounter hesitancy should persist
in offering recommendations, while understanding that
parents’ concerns and communication preferences vary. By
developing targeted strategies, future studies may provide a
way to better meet parents’ communication needs, thereby
increasing the acceptance of HPV vaccination and, in turn,
adolescents’ protection against future HPV-associated cancers.
Methods
Participants
We surveyed parents of adolescents in November 2014 to
January 2015. Parents were members of a nationally-represen-
tative, online panel of US adults maintained by a survey
research company.10 The survey company constructed the
panel using a dual-frame sampling approach consisting of ran-
dom digit dialing supplemented by address based sampling;
this approach provided coverage for households with and with-
out landline telephones. Panel members were eligible to partici-
pate if they were the parent of an 11- to 17-year-old child. To
facilitate the ongoing participation of low-resource households,
the survey company provided internet access and an electronic
device for panel members who lacked these resources. Other
members received points redeemable for small cash payments.
The survey company invited 2,845 parents to participate, and
1,504 parents were eligible and completed the survey. Our
response rate, calculated using American Association for Public
Opinion Research Response Rate 5, was 61%11 For this study, we
excluded respondents who did not provide data on whether they
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had ever refused or delayed HPV vaccine (n D 20). Our final
analytic sample consisted of 1,484 parents. The University of
North Carolina Institutional Review Board approved this study.
Measures
Our survey assessed HPV vaccine refusal and delay using 2 sep-
arate items from the 2010 NIS-Teen12: “Has there ever been a
time when you [refused or decided not to get/delayed or put off
getting] the HPV vaccine for [NAME]?” Separately for each
item, parents who responded “yes” next indicated their reason
(s) for refusal or delay, using a list of 10 response options. We
categorized parents as having refused HPV vaccine (with or
without delay), delayed only, or neither delayed nor refused.
We combined parents who had refused only with those who
had both refused and delayed based on prior research that sug-
gests similarities between these groups in terms of HPV vac-
cine-related knowledge, attitudes, and behavior.9
Our survey assessed HPV vaccination status with one item:
“How many shots of the HPV vaccine has [NAME] had?”6 We
defined HPV vaccine initiation as responses of one or more
shots. For adolescents who had not completed the HPV vaccine
series, the survey also assessed parents’ intention to get HPV
vaccine in the next year.
Our survey assessed 4 constructs related to parents’ vaccine-
related perceptions. One item assessed the perceived effective-
ness of HPV vaccine (“effectiveness”), 2 items assessed
perceived harms of HPV vaccine (“harms”), one item assessed
the perceived need for more information about HPV vaccine
(“uncertainty”), and 4 items assessed confidence about adoles-
cent vaccination more generally (“vaccination confidence”).
We adapted these items from 2 validated measures of vaccina-
tion beliefs.13-15 All items used response scales that ranged
from 1 (“strongly disagree”) to 5 (“strongly agree”). For con-
structs with multiple items, we averaged responses across items.
For each construct, we then categorized responses as “low”
(3) or “high” (>3).
Our survey assessed preferences for clinical communication
about HPV vaccination with 4 items. Parents rated information
sources, such as talking to a doctor, in terms of whether they
would be helpful for making a decision about HPV vaccination.
Parents also indicated the age at which they believed providers
should start recommending HPV vaccine. Based on guidelines
for HPV vaccine administration,16 we categorized responses as
“on time” (by age 12), “late” (age 13 or older), or “never.”
Finally, parents reported their preferred timeframe for decision
making: same-day decision after little or no discussion with a
provider; same-day decision after a long discussion; or decision
at a later visit.
Our survey assessed the demographic characteristics of chil-
dren on sex, age, and race/ethnicity. The survey company pro-
vided data on parents’ sex, educational attainment, annual
household income, and state of residence.
Statistical analysis
We calculated the prevalence of HPV vaccine refusal and delay
for the overall sample as well as for girls, ages 13–17. We
performed the latter subgroup analysis to facilitate comparison
with 2010 NIS-Teen findings. We used chi-squared tests to
assess differences in survey responses by refusal/delay category.
We used multinomial logistic regression to simultaneously
identify bivariate correlates of HPV vaccine refusal and delay, as
compared to neither refusal nor delay. We then entered statisti-
cally significant correlates (p < 0.05) into a multivariable model.
Our analyses used survey weights to generate nationally-rep-
resentative estimates. We conducted analyses data using Stata
Version 12.0 (College Station, TX). Statistical tests were 2-tailed
with a critical alpha of 0.05.
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